Thromb Haemost 1993; 69(05): 448-453
DOI: 10.1055/s-0038-1651631
Original Article
Coagulation
Schattauer GmbH Stuttgart

Activation of Protein C and Its Distribution between Its Inhibitors, Protein C Inhibitor, α1-Antitrypsin and α2-Macroglobulin, in Patients with Disseminated intravascular Coagulation

M F Scully
1   The Department of Haematology, Royal Victoria Hospital Montreal, Quebec
,
C H Toh
The Departments of Pathology, Biochemistry and Medicine Queen’s University, Kingston, Ontario, Canada
,
H Hoogendoorn
The Departments of Pathology, Biochemistry and Medicine Queen’s University, Kingston, Ontario, Canada
,
R P Manuel
The Departments of Pathology, Biochemistry and Medicine Queen’s University, Kingston, Ontario, Canada
,
M E Nesheim
The Departments of Pathology, Biochemistry and Medicine Queen’s University, Kingston, Ontario, Canada
,
S Solymoss
1   The Department of Haematology, Royal Victoria Hospital Montreal, Quebec
,
A R Giles
The Departments of Pathology, Biochemistry and Medicine Queen’s University, Kingston, Ontario, Canada
› Author Affiliations
Further Information

Publication History

Received 11 May 1992

Accepted after revision 26 January 1993

Publication Date:
25 July 2018 (online)

Summary

Activation and inactivation of protein C during the clinical course of disseminated intravascular coagulation (DIC) was studied in three patients by qualitative (Western blotting) and quantitative (ELISA) analysis and the intensity of procoagulant activity monitored by the measurement of thrombin and factor Xa antithrombin III complexes. In one patient, inhibitor complexes of APC with protein C inhibitor (PCI) and α1-antitrypsin (α1-AT) were observed and the latter predominated at presentation. Both disappeared during the development of remission but the loss of α1-AT complexes preceded PCI complexes which on Western blotting appeared to increase in intensity prior to disappearance. The two other patients bled to death from uncontrollable haemorrhage. In both cases, APC/inhibitor complexes with α2-macroglobulin (α2-M) in addition to PCI and αr-AT were detected and persisted until death. Although PCI appeared to be the primary inhibitor in all three cases, α1-antitrypsin and particularly α2-macroglobulin appeared to assume greater roles in the two fatal cases. These data are similar to previous findings in an experimental animal model of DIC that suggested that α2-macroglobulin and α1-antitrypsin become more important inhibitors of APC as the primary inhibitor PCI is consumed in the face of a sustained procoagulant challenge.

 
  • References

  • 1 McKay DG. Disseminated Intravascular Coagulation. New York: Harper-Hoeber; 1965: 493
  • 2 Deykin D. The clinical challenge of disseminated intravascular coagulation. N Engl J Med 1970; 283: 636-644
  • 3 Giles AR, Nesheim ME, Mann KG. Studies of factors V and VIII: C in an animal model of disseminated intravascular coagulation. J Clin Invest 1984; 74: 2219-2225
  • 4 Giles AR, Mann KG, Nesheim ME. A Combination of factor Xa and phosphatidylcholine-phosphatidylserine vesicles bypasses factor VIII in vivo. Br J Haematol 1988; 69: 491-497
  • 5 Hoogendoorn H, Nesheim ME, Giles AR. A qualitative and quantitative analysis of the activation and inactivation of protein C in vivo in a primate model. Blood 1990; 75: 2164-2171
  • 6 Hoogendoorn H, Toh CH, Nesheim ME. et al. Alpha-2-Macroglobulin binds and inhibits activated protein C. Blood 1991; 78: 2283-2290
  • 7 Heeb MJ, Mosher DF, Griffin JH. Activation and complexation of protein C and cleavage and decrease of protein S in plasma of patients with intravascular coagulation. Blood 1989; 73: 455-461
  • 8 Tracy PB, Giles AR, Mann KG. et al. Factor V (Quebec): a bleeding diathesis associated with a qualitative platelet factor V deficiency. J Clin Invest 1984; 74: 1221-1228
  • 9 Clauss VA. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-246
  • 10 Koide T. Isolation and characterization of antithrombin III from human, porcine and rabbit plasma, and rat serum. J Biochem 1979; 86: 1841-1850
  • 11 Hall PK, Roberts RC. Physical and chemical properties of human plasma alpha(2)-macroglobulin. Biochem J 1978; 171: 27-38
  • 12 Travis J, Salvesen GS. Human plasma proteinase inhibitors. Annu Rev Biochem 1983; 52: 655-709
  • 13 Suzuki K, Nishioka J, Kusumoto H. et al. Mechanism of inhibition of activated protein C by protein C inhibitor. J Biochem 1984; 95: 187-195
  • 14 Butkowski RJ, Elion J, Downing MR. et al. Primary structure of human prethrombin 2 and alpha thrombin. J Biol Chem 1977; 252: 4942-4957
  • 15 Kisiel WK. Human plasma protein C. Isolation, characterization, and mechanism of activation by (alpha)-thrombin. J Clin Invest 1979; 64: 761-769
  • 16 DiScipio RG, Hermodson MA, Yates SG. et al. A comparison of human prothrombin, factor IX (Christmas factor), factor X (Stuart factor), and protein S. Biochemistry 1977; 16: 698-705
  • 17 Heeb MJ, Gruber A, Griffin JH. Identification of divalent metal iondependent inhibition of activated protein C by alpha(2)-Macroglobulin and alpha(2)-Antiplasmin in blood and comparisons to inhibition of factor Xa, thrombin, and plasmin. J Biol Chem 1991; 266: 17606-17612
  • 18 Espana F, Vicente V, Tabernero D. et al. Determination of plasma protein C inhibitor and of two activated protein C-inhibitor complexes in normals and in patients with intravascular coagulation and thrombotic disease. Thromb Res 1990; 59: 593-608
  • 19 Griffin JH, Mosher DF, Zimmerman TS. et al. Protein C, an antithrombotic protein, is reduced in hospitalized patients with intravascular coagulation. Blood 1982; 60: 261-264
  • 20 Mimuro J, Sakata Y, Wakabayashi K. et al. Level of protein C determined by combined assays during disseminated intravascular coagulation and oral anticoagulation. Blood 1987; 69: 1704-1711
  • 21 Laurell M, Stenflo J, Carlson TH. Turnover of I-protein C inhibitor and I-alpha(1)-Antitrypsin and their complexes with activated protein C. Blood 1990; 76: 2290-2295
  • 22 Espana F, Gruber A, Heeb MJ. et al. In vivo and in vitro complexes of activated protein C with two inhibitors in baboons. Blood 1991; 77: 1754-1760
  • 23 Taylor Jr FB, Hoogendoorn H, Chang ACK. et al. Anticoagulant and fibrinolytic activities are promoted not retarded in vivo following thrombin generation in the presence of a monoclonal antibody that inhibits activation of protein C. Blood 1992; 79: 1720-1728
  • 24 Giles AR, Nesheim ME, Herring SW. et al. The fibrinolytic potential of the normal primate following the generation of thrombin in vivo. Thromb Haemostas 1990; 63: 476-481
  • 25 Clouse LH, Comp PC. The regulation of hemostasis: The protein C system. N Engl J Med 1986; 314: 1298-1304
  • 26 Marder VJ, Martin SE, Francis CW. et al. Consumptive throm-bohemorrhagic disorders. In: Hemostasis and Thrombosis. Colman RW, Hirsh J, Marder VJ. et al. (eds). Philadelphia: Lippincott; 1987: 975-1015
  • 27 Taylor Jr FB, Chang A, Esmon CT. et al. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987; 79: 918-925
  • 28 Okajima K, Imamura H, Koga S. et al. Treatment of patients with disseminated intravascular coagulation by protein C. Am J Hematol 1990; 33: 277-278